抗血小板药物联合应用在冠心病患者中的可行性与安全性分析

目的：探讨氯吡格雷联合阿司匹林抗血小板治疗冠心病老年患者的可行性和安全性。方法：选取本院2012年1月-2013年6月收治的老年冠心病患者100例，按随机数字表法分为观察组和对照组，每组各50例。对照组给予阿司匹林；观察组给予氯吡格雷联合阿司匹林。观察两组的血小板计数、血小板聚集率、出血率及凝血三项。结果：治疗后，两组血小板计数和血小板聚集率较治疗前均明显降低（P〈0．05），出血率与治疗前比较差异无统计学意义（P〉0．05）；两组间血小板计数、出血率比较，差异无统计学意义（P〉0．05），但在治疗6个月和12个月时，观察组血小板聚集率疗效优于对照组（P〈0．05）；两组治疗前后及两组间的凝血三项比较变化均不明显。结论：采用氯吡格雷联合阿司匹林双联疗法疗效治疗老年冠心病患者临床疗效显著，安全可行。

Analysis of Feasibility and Safety of Combined Use of Antiplatelet Agents in Patients with Coronary Heart Disease

Objective： To explore the combination of feasibility and safety of clopidogrel and aspirin antiplatelet therapy for coronary heart disease in elderly patients. Method： 100 elderly patients with coronary heart disease in our hospital from January 2012 to June 2013 were randomly divided into observation group and control group , 50 cases in each group. The control group were given aspirin; the observation group were treated with clopidogrel and aspirin. The platelet count, platelet aggregation rate, two groups of hemorrhage and coagulation three were observed. Result： After treatment, platelet count and platelet aggregation rate of two groups significantly decreased compared with those before treatment （ P〈0.05 ） . Bleeding rate had no significant difference compared with before treatment （ P〉0.05 ） ; there were no significant differences between the two groups about the platelet count, rate of hemorrhage （ P〉0.05 ） . The platelet count, rate of hemorrhage of the two groups had no significant difference （ P〉0.05 ）, but the rate of platelet aggregation effect of the observation group was better than the control group after treatment for 6 months and 12 months （ P〈0.05 ） . In the two groups before and after treatment and between the two groups, changes in three items of blood coagulation were not obvious. Conclusion： The combination double therapy treatment of elopidogrel and aspirin of elderly patients with coronary heart disease is significantly, safe and feasible.